In this comprehensive study of the T-cell response to EBV in MS, we have shown thatthere is a decreased CD8+ T-cell response to EBV lytic phase antigensat the onset of MS and at all subsequent stages of the disease. This evidence concerns the gene CD8A and myeloid sarcoma.